The combination of the anti-CD47 antibody and anthracyclines has shown good therapeutic efficacy for orthotopic breast cancer; this antibody eliminates M2 macrophages and Tregs in the tumor microenvironment [96]. This evidence concerns the gene CD47 and neoplasm.